Attune Neurosciences

Executive Summary

Attune Neurosciences is pioneering the first wearable, non-invasive ultrasound system for deep brain therapy, combining MRI-guided precision with adaptive stimulation. Founded in 2021 and headquartered in San Diego, the company aims to revolutionize treatments for neurological disorders and enhance human performance. Its proprietary technology delivers focused ultrasound through a wearable device, enabling targeted modulation of deep brain circuits without surgery. This approach could address major unmet needs in conditions like depression, Parkinson's disease, and chronic pain, offering a safer, more accessible alternative to invasive procedures. The system's real-time feedback capability allows personalized therapy, potentially improving outcomes and reducing side effects. While still in early development, Attune attracts interest for its innovative platform that merges neuroscience, imaging, and device engineering. The company has yet to disclose funding or clinical milestones but is positioned as a disruptor in the neurotechnology space, with significant implications for both therapeutic and performance applications. Its success hinges on demonstrating safety and efficacy in upcoming studies.

Upcoming Catalysts (preview)

• Q4 2026Launch of First-in-Human Clinical Trial60% success
• Q3 2026Series A Financing Round Closure70% success
• TBDFDA Pre-Submission Meeting Outcome80% success